Abstract
The changes in electrical activity of neurons have been indirectly attributed to the alterations in regional cerebral blood flow or local cerebral glucose metabolic rate. However, brain function is directly related to neural signaling and transmission of electrical activity via chemical and electrical synapses. A number of new targeted molecular imaging probes, specifically designed for diagnosis, and to assess treatment response in brain disorders associated with either structural or functional abnormalities, are under clinical evaluation. This chapter provides a broad overview of the design, synthesis, and development of molecular radiopharmaceuticals in the assessment of cerebral glucose metabolism, perfusion, neurotransmission, and Aβ amyloid deposition. This chapter also discusses the potential clinical utility of neuro-PET and neuro-SPECT techniques in the diagnosis of Alzheimer’s disease (AD), Parkinson’s disease (PD), primary and recurrent brain tumors, epilepsy, and ischemic stroke. In psychiatric diseases, such as schizophrenia, depression, and drug abuse, the role of neuroreceptor imaging techniques in the quantification of receptor occupancy and dose-response relationship is also briefly addressed.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Keywords
- Positron Emission Tomography
- Positron Emission Tomography Imaging
- Dementia With Lewy Body
- Positron Emission Tomography Study
- Dopamine Transporter
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Abi-Dargham A, Martinez D, Mawlavi O, et al (2000a) Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC-112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20:225–243
Abi-Dargham A, Rodenhiser J, Printz D, et al (2000b) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 97(14):8104–8109
Agdeppa ED, Kepe V, Liu J, et al (2001) Binding characteristics of radiofl uorinated 6-dialkyl-amino-2-naphtylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease. J Neurosci 21:1–5
Archer HA, Edison P, Brooks DJ, et al (2006) Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 60:145–147
Banati RB, Newcombe J, Gunn RN, et al (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123:2321–2337
Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152
Barrio JR, Huang S-C, Cole G, et al (1999) PET imaging of tangles and plaques in Alzheimer's disease with a highly hydrophobic probe. J Label Compd Radiopharm 42:S194
Bartus RT, Dean RL, Beer B, et al (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–17
Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358:55–68
Bremmer JD, Horti A, Staib LH, et al (2000) Kinetic modeling of benzodiazepine receptor binding with PET and high specifi c activity [11C]iomazenil in healthy human subjects. Synapse 35:68–77
Blasberg RG, Tjuvajev JG (2003) Molecular-genetic imaging: current and future perspectives. J Clin Invest 111:1620–1629
Bohnen NI, Frey KA (2003) The role of positron emission tomography imaging in movement disorders. Neuroimaging Clin N Am 13:791–803
Boutin H, Chauveau F, Thominiaux C (2007) 11C-DPA-713: a novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinfl ammation J Nucl Med 48:573–581
Breier A, Su TP, Saunders R, et al (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94(6):2569–2574
Brooks DJ (2003) PET studies on the function of dopamine in health and Parkinson's disease. Ann N Y Acad Sci 991: 22–35
Brooks DJ (2005) Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx 2:226–236
Buckner RL (2004) Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 44: 195–208
Casse R, Rowe CC, Newton M, et al (2002) Positron Emission Tomography and Epilepsy Mol Imaging Biol 4:338–351
Chaly T, Dhawan V, Kazumata K, et al (1996) Radiosynthesis of [18F]N-3-fl uoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography. Nucl Med Biol 23:999–1004
Chou KL, Hurtig HI, Stern MB, et al (2004) Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson's disease. Parkinsonism Relat Disord 10:375–379
Crone C (1964) Permeability of capillaries in various organs as determined by the use of indicator diffusion method. Acta Physiol Scand 58:292–305
Cunningham VJ, Gunn RN, Matthews JC (2004) Quantifi cation in positron emission tomography for research in pharmacology and drug development. Nucl Med Commun 25: 643–646
Davis MR, Votaw JR, Bremner JD, et al (2003) Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med 44:855– 861
Dickson DW (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56:321–339
Diksic M, Tohyama Y, Takada A (2000) Brain net unidirectional uptake of α-methyltryptophan. Neurochem Res 25: 1537–1546
Ding YS, Fowler J (2005) New-generation radiotracers for nAChR and NET. Nucl Med Biol 32:707–718
Ding Y-S, Fowler JS, Volkow ND, et al (1994) Pharmacokinetics and in vivo specifi city of [11C]DL-threo-methylphenydate for the presynaptic dopaminergic neuron. Synapse 18: 152–160
Ding Y-S, Volkow ND, Logan J, et al (2000) Occupancy of brain nicotinic acetylcholine receptors by nicotine doses equivalent to those obtained when smoking a cigarette. Synapse 35:234–237
Drzezga A (2008) Basic pathologies of neurodegenerative dementias and their relevance for state-of-the-art molecular imaging studies. Eur J Nucl Med Mol Imaging 35:S4–S11
Eckelman WC (2001) Radiolabeled muscarinic radioligands for in vivo studies. Nucl Med Biol 28:485–491
Eckelman WC, Grissom M, Conklin J, et al (1984) In vivo competition studies with analogues of quinucidinylbenzilate. J Pharm Sci 73:529–533
Eckert T, Eidelberg D (2005) Neuroimaging and therapeutics in movement disorders. NeuroRx 2:361–371
Eshuis SA, Maguire RP, Leenders KL, et al (2006) Comparison of FP-CIT SPECT with FDOPA- PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging 33:200–209
Farde L, Ehrin E, Eriksson L, et al (1985) Substituted benz-amides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A 82:3863–3867
Farde L, Wiesel FA, Halldin C, et al (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45(1):71–76
Farde L, Nordstrom AL, Wiesel FA, et al (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544
Firnau G, Sood S, Chirakal R, et al (1988) Metabolites of 6-[18F] fluoro-L-dopa in human blood. J Nucl Med 29:363–369
Fischman AJ, Bonab AA, Babich JW, et al (2001) [11C, 127I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 39:332–342
Fischman AJ (2005) Role of [18F]-dopa–PET imaging in assessing movement disorders. Radiol Clin N Am 43:93–106
Fowler JS, MacGregor RR, Wolf AP, et al (1987a) Mapping human brain monoamine oxidase A and B with 11C-suicide inactivators and positron emission tomography. Science 235:481–485
Fowler JS, Volkow ND, Wolf AP, et al (1987b) Mapping cocaine binding in human and baboon brain in vivo. Synapse 4:371–377
Fowler JS, Volkow ND, Wang G-J, et al (1996) Inhibition of monoamine oxidase B in the brains of smokers. Nature 379:733–736
Fowler JS, Ding Y-S, Volkow ND (2003) Radiotracers for Positron Emission Tomography Imaging. Semi Nucl Med 33:14–27
Frackowiak RS, Lenzi GL, Jones T, et al (1980) Quantitative measurement of regional cerebral blood flow and oxygen metabolism in man 15O and positron emission tomography: theory, procedure and normal values. J Comput Assisted Tomogr 4:727–736
Frankle WG, Laruelle M (2002) Neuroreceptor imaging in psychiatric disorders. Ann Nucl Med 16(7):437–446
Frey KA, Koeppe RA, Kilbourn MR, et al (1996) Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 40:873–884
Frey KA, Koeppe RA, Kilbourn MR (2001) Imaging the vesicular monoamine transporter. Adv Neurol 86:237–247
Frost JJ (2001) PET imaging of the opioid receptor. The early years. Nucl Med Biol 28:509–513
Frost JJ, Wagner Henry JJ, Danals RF, et al (1985) Imaging opiate receptors in the human brain by positron emission tomography. J Comput Asstisted Tomogr 9:231–236
Garnett ES, Firnau G, Nahmias C (1983) Dopamine visualized in the basal ganglia in living human brain. Nature 305–137–138
Garnett ES, Nahmias C, Firnau G (1984) Central dopaminergic pathways in hemiparkinsonism examined by positron emission tomography. Can J Neurol Sci 11:174–179
Gibb AJ. Neurotransmitter receptors. In: Webster RA, ed. Neurotransmitters, drugs and brain function. Wiley, New York, NY, pp 57–79
Gilman S, Koeppe RA, Junck L, et al (1995) Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography. Ann Neurol 38:176–185
Ginovart N, Wilson AA, Meyer JH, et al (2003) [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats. Synapse 47:123–133
Goffin K, Dedeurwaerdere S, Van Laere K, et al (2008) Neuronuclear assessment of patients with epilepsy. Semin Nucl Med 38:227–239
Gulyas B, Halldin C, Sandell J, et al (2002) PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol Scand 106:325–332
Halldin C, Farde L, Hogberg T, et al (1995) Carbon-11-FLB 457: a radioligand for extra-striatal D2 dopamine receptors. J Nucl Med 36:1275–1281
Hammoud DA, Endres CJ, Chander AR, et al (2005) Imaging glial cell activation with [11C]-R-PK11195 in patients with AIDS. J Neurovirol 11:346–355
Hammoud DA, Hoffman JM, Pomper MG (2007) Molecular neuroimaging: from conventional to emerging techniques. Radiology 245:21–42
Harpstrite SE, Prior J, Piwnica-Worms D, et al (2005) Peptide conjugates for imaging-amyloid in the brain. J Label Compd Radiopharm 48(s1):S228
Henriksen G, Yousefi BH, Drzezga A, et al (2008) Development and evaluation of compounds for imaging of β-amyloid plaque by means of positron emission tomography. Eur J Nucl Med Mol Imaging 35(Suppl 1):S75–S81
Herscovitch P, Markham J, Raichle ME (1983) Brain blood flow measured with intravenous [15O] water, I: theory and error analysis. J Nucl Med 24:782–789
Heiss WD, Herholz K (2006) Brain receptor imaging. J Nucl Med 47:302–312
Herholz K (2008) Acetylcholine esterase activity in mild cognitive impairment and Alzheimer's disease. Eur J Nucl Med Mol Imaging 35(Suppl 1):S25–S29
Herholz K, Heiss WD (2004) Positron emission tomography in clinical neurology. Mol Imaging Biol 6:239–269
Herholz K, Herscovitch P, Heiss W-D (2004). NeuroPET. Springer, Berlin
Holman BL, Gibson RE, Hill TC, et al (1985) Muscarinic acetylcholine receptors in Alzheimer's disease: in vivo imaging with iodine 123-labeled 3-quinuclidinyl-4-iodobenzilate and emission tomography. JAMA 254:3063–3066
Hume SP, Gunn RN, Jones T (1998) Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur J Nucl Med 25:173–176
Hustinx R, Pourdehnad M, Kaschten B, Alavi A (2005) PET imaging for differentiating recurrent brain tumor from radiation necrosis Radiol Clin North Am 43:35–47
Jack CR Jr, Lowe VJ, Senjem ML, et al (2008) 11C PIB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 131:665–680
Jacobs A, Voges J, Reszka R, et al (2001) Positron-emission tomography of vector mediated gene expression in gene therapy for gliomas. Lancet 358:727–729
Jacobs AH, Li H, Winkeler A, et al (2003) PET-based molecular imaging in neuroscience Eur J Nucl Med Mol Imaging 30:1051–1065
Jacobs AH, Winkler A, Castro MG, et al (2005) Human gene therapy and imaging in neurological diseases. Eur J Nucl Med Mol Imag 32:S358–S383
Jagust W (2004) Molecular neuroimaging in Alzheimer's disease. Neuro Rx 1:206–212
Jennings DL, Seibyl JP, Oakes D, et al (2004) (123I) beta-CIT and single photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 61:1224–1229
Jones T, Chesler DA, Ter-Pogossian MM, et al (1976) The continuous inhalation of oxygen-15 for assessing regional oxygen extraction in the brain of man. Br J Radiol 49:339–343
Juhasz C, Chugani HT (2003) Imaging the epileptic brain with positron emission tomography. Neuroimaging Clin N Am 13:705–716
Kapur S, Remington G (2001) Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be suffi cient. Biol Psychiatry 50(11):873–883
Kapur S, Zipursky R, Jones C, et al (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently
Kapur S, Zipursky R, Jones C, et al (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553–559
Kato H, Shimosegawar E, Oku N, et al (2008) MRI-based correction for partial-volume effect improves detectability of intractable epileptogenic foci on 123I-Iomazenil brain SPECT images. J Nucl Med 49:383–389
Kauppinen T, Bergstrom K, Heikman P, et al (2003) Biodistribution and radiation dosimetry of [1231]ADAM in healthy human subjects: preliminary results. Eur J Nucl Med 30:132–136
Kemppainen NM, Aalto S, Wilson IA, et al (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603–1606
Kirik D, Breysse N, Björklund T (2005) Imaging in cell-based therapy for neurodegenerative diseases. Eur J Nucl Med Mol Imaging 32:S417–S434
Kling MA, Carson RE, Borg L, et al (2000) Opioid rcecptor imaging with positron emission tomography and [18F]cyclo-foxy in long-term, methadone-treated former heroin addicts. J Pharm Exp Ther 295:1070–1076
Klunk WE, Wang Y, Huang G-F (2003) The binding of 2-(4′-eth-ylaminophenyl)benzothiazole to postmortem brain homoge-nates is dominated by the amyloid component. J Neurosci 23(6):2086–2092
Klunk WE, Engler H, Nordberg A, et al (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 55:306–319
Koeppe RA, Frey KA, Snyder SE, et al (1999) Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab19:1150–1163
Koob GF, Bloom FE (1988) Cellular and molecular mechanisms of drug dependence. Science 242:715–723
Kudo Y, Okamura N, Furumoto S, et al (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]Ethenyl)-6-(2-[Fluoro]Ethoxy) Benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 48:553–561
Kuhl DE, Koeppe RA, Minoshima S, et al (1999) In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 52:691–699
Kuhl DE, Minoshima S, Frey KA, et al. (2000) Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 48:391–395
Kulak JM, Sum J, Musachio JL, et al (2002): 5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcho-line receptors (nAChRs) as well as alpha4beta2* subtypes. J Neurochem 81:403–406
Kung HF, Kung M-P, Choi SR (2003a) Radiopharmaceuticals for single-photon emission computed tomography brain imaging. Semin Nucl Med 33:2–13
Kung HF, Kung M-P, Zhuang ZP, (2003b) Iodinated tracers for imaging amyloid plaques in the brain. Mol Imaging Biol 5:418–426
Kumar A, et al (2003) Brain 126:2648–2655
Laruelle M, Abi-Dargham A, van Dyck CH, et al (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 93(17):9235–9240
Laruelle M, Talbot P, Martinez D, et al (2002) Psychiatric disorders. In: Wahl RL (ed) Principles and Practice of positron emission tomography, Lippincott Williams & Wilkins, Philadelphia
Ma Y, Dhawan V, Mentis M, Chaly T, et al (2002) Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study. Synapse 45:125–133
Ma B, Sherman PS, Moskwa JE, et al (2004) Sensitivity of [11C] N-methylpyrroli-dinyl benzilate ([11C]NMPYB) to endogenous acetylcholine: PET imaging vs tissue sampling methods. Nucl Med Biol 31:393–397
Machulla H-J, Heinz A (2005) Radioligands for brain imaging of the κ-opioid system. J Nucl Med 46:386–387
Maeda J, Suhara T, Zhang MR, et al (2004) Novel peripheral benzodiazepine receptor ligand [11C]DAA1106 for PET: an imaging tool for glial cells in the brain. Synapse 52:283–291
Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 103:5644–5651
Markus R, Donnan GA, Kazui S, et al (2002) Statistical parametric mapping of hypoxic tissue identifi ed by [18F] fluoromisonidazole and positron emission tomography following acute ischemic stroke. Neuroimage 16:425–433
Marshall V, Grosse D (2003) Role of dopamine transporter imaging in routine clinical practice. Mov Disord 18:1415–1423
Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545–580
Mathis CA, Bacskai BJ, Kajdasz ST, et al (2002) A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12:295–298
Mathis CA, Wang Y, Klunk WE (2004) Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 10:1469–1492
Mathis CA, Loprestia BJ, Klunk WE (2007) Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 34:809–822
Mazziotta JC, Phelps ME, Miller J (1981) Tomographic mapping of human cerebral metabolism. Neurology 31:503–516
Meltzer CC, Cantwell MN, Greer PJ, et al (2000) Does cerebral blood flow decline in healthy aging? A PET study with partial volume correction. J Nucl Med 41:1842–1848
Merlet I, Ostrowsky K, Costes N, et al (2004) 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. Brain 127:900–913
Meyer JH (2008) Applying neuroimaging ligands to study major depressive disorder. Semin Nucl Med 38:287–304
Meyer J, Kapur S, Houle S, et al (1999) Prefrontal cortex 5-HT2 receptors in depression: a [18F]setoperone PET imaging study. Am J Psychiatry 156(7):1029–1034
Meyer JH, Kruger S, Wilson AA, et al (2001a) Lower dopamine transporter binding potential in striatum during depression. Neuroreport 12(18):4121–4125
Meyer JH, Wilson AA, Ginovart N, et al (2001b) Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry 158(11):1843–1849
Meyer JH, McMain S, Kennedy SH, et al (2003) Dysfunctional attitudes and 5-HT(2) receptors during depression and self-harm. Am J Psychiatry 160(1):90–99
Meyer JH, Wilson AA, Sagrati S, et al (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161(5):826–835
Mintun MA, Larossa GN, Sheline YI, et al (2006) [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446–452
Morris JH, Nagy Z (2004) Alzheimer's disease. In: Esiri MM, Lee VM, Trojanowski JQ (eds) The neuropathology of dementia, 2nd edn. Cambridge University Press, Cambridge, UK
Mozley PD, Schneider JS, Acton PD, et al (2000) Binding of 99mTc-TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 41:584–589
Mukherjee J, Kang ZY, Brown T, et al (1999) Preliminary assessment of extrastriatal dopamine D2 receptor binding in the rodent and nonhuman primate brains using the high affi nity radioligand, 18F-Fallypride. Nucl Med Biol 26:519–527
Newberg AB, Alavi A (2005) PET in seizure disorders. Radiol Clin North Am 43:79–92
Ng S, Villemagne VL, Berlangieri S, et al (2007) Visual assessment versus quantitative assessment of [11C]PIB PET and [18F]FDG PET for detection of Alzheimer's disease. J Nucl Med 48:547–552
Nordberg A (2008) Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging 35:S46–S50
Parsey RV, Mann JJ (2003) Applications of positron emission tomography in psychiatry. Semin Nucl Med 33(2):129–135
Pappata S, Tavitian B, Traykov L, et al (1996) In vivo imaging of human cerebral acetylcholinesterase. J Neurochem 67:876–879
Passchier J, van Waarde A (2001) Visualization of serotonin-1A (5-HT1A) receptors in the central nervous system. Eur J Nucl Med 28:113–129
Passchier J, van Waarde A, Pieterman RM, et al (2000) In vivo delineation of 5-HT1A receptors in human brain with [18F] MPPF. J Nucl Med 41:1830–1835
Persson A, Ehrin E, Eriksson, et al (1985) [11C]Ro-15–1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. J Psychiatry Res 19: 609–622
Petrella JR, Mattay VS, Doraiswamy PM (2008) Imaging genetics of brain longevity and mental wellness: the next frontier? Radiology:246:20–32
Podruchny TA, Connolly C, Bokde A, et al (2003) In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48:39–44
Price JL (1997) Diagnostic criteria for Alzheimer's disease. Neurobiol Aging 18:S67–S70
Phelps ME, Huang SC, Hoffman EJ, et al (1979) Tomographic measurement of local cerebral glucose metabolic rate in human with [18F]2-fl uoro-2-deoxyglucose. Validation of method. Ann Neurol 6:371–388
Pike VW (1995) Radioligands for PET studies of central 5-HT receptors and re-uptake sites- current status. Nucl Med Biol 22:1011–1018
Pike KE, Savage G, Villemagne VL, et al (2007) β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130:2837–2844
Raichle ME, Martin WRW, Herscovitch P, et al (1983) Brain blood fl ow measured with intravenous H2 15O. II. Implementation and validation. J Nucl Med 24:790–798
Ravina B, Eidelberg D, Ahlskog JE, et al (2005) The role of radiotracer imaging in Parkinson disease. Neurology 64:208–215
Read SJ, Hirano T, Abbott DF, et al (1998) Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluo-romisonidazole. Neurology 51:1617–1621
Reiman EM, Chen K, Alexander GE, et al (2004) Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A 101:284–289
Reivich N, Kuhl D, Wolf A, et al (1979) The [18F] Fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44:127–137
Robeson W, Dhawan V, Belakhlef A, et al. (2003) Dosimetry of the dopamine transporter radioligand 18F-FPCIT in human subjects. J Nucl Med 44:961–966
Rosas HD, Feigin AS, Hersch SM (2004) Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx 1:263–272
Rowe CC, Ng S, Ackermann U, et al (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68:1718–1725
Rowe CC, Ackerman U, Browne W, et al (2008) Imaging of amyloid β in Alzheimer's disease with 18F-BAY94–9172, a novel PET tracer: proof of mechanism. Lancet Neurol 7:129–35
Ryzhikov NN, et al (2005) Preparation of highly specific radioactivity [18F]flumazenil and its evaluation in cynomolgus monkey by positron emission tomography. Nucl Med Biol 32:109–116
Sabri O, Kendziorra K, Wolf H, et al (2008) Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 35(s1):S30–S45
Saur D, Buchert R, Knab R, et al (2006) Iomazenil-single-photon emission computed tomography reveals selective neuronal loss in magnetic resonance-defined mismatch areas. Stroke 37:2713–2719
Seibyl JP (2008) Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. Semin Nucl Med 38:274–286
Selleri S, Bruni F, Costagli C, et al (2001) 2-Arylpyrazolo[1,5-a] pyrimidin-3-yl acetamides: new potent and selective peripheral benzodiazepine receptor ligands. Bioorg Med Chem 9:2661–2671
Shiue C-Y, Welch MJ (2004) Update on PET radiopharmaceuticals: life beyond fl uorodeoxyglucose. Radiol Clin N Am 42:1033–1053
Shoghi-Jadid K, Small GW, Agdeppa ED, et al (2002) Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10:24–35
Siesjo BK (1978) Brain energy metabolism. Wiley, New York, pp 101–110
Silverman DHS (2004) Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45:594–607
Silverman DHS, Mosconi L, Ercoli L, et al (2008) Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med 38:251–261
Small GW, Kepe V, Ercoli LM, et al (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652–2663
Smith GS, Koppel J, Goldberg S (2003) Applications of neuroreceptor imaging to psychiatry research. Psychopharmacol Bull 37:26–65
Suhara T, Maeda J, Kawabe K, et al (2003a) Visualization of alpha5 subunit of GABAA/benzodiazepine receptor by [11C] Ro15–4513 using positron emission tomography. Synapse 47:200–208
Suhara T, Takano A, Sudo Y, et al (2003b) High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60(4):386–391
Sullivan JP, DonnellyRD, Briggs CA, et al (1996) A-85380 [3-(2(S)-azetidinylmethoxy)-pyridine]: in vitro pharmacological properties of a novel, high affi nity α4β2 nicotinic acetylcholine receptor ligand. Neuropharmacology 35:725–734
Szelies B, Sobesky J, Pawlik G, et al (2002) Impaired benzodiazepine receptor binding in peri-lesional cortex of patients with symptomatic epilepsies studies by [C-11]-flumazenil PET. Eur J Neurol 9:137–142
Talbot PS, Narendran R, Butelman ER, et al (2005) [11C] GR103545, a radiotracer for imaging K-opioid receptors in vivo with PET: synthesis and evaluation in baboons J Nucl Med 46:484–494
Ter-Pogossian MM, Eichling JO, Davis DO, et al (1969) The determination of regional cerebral blood flow by means of water labeled with radioactive oxygen-15. J Clin Invest 93:31–40
Theodore WH (2004) Recent advances and trends in epilepsy imaging: pathogenesis and pathophysiology. Rev Neurol Dis 1(2):53–59
Thominiaux C, Dolle F, James ML, et al (2006) Improved synthesis of the peripheral benzodiazepine receptor ligand [11C] DPA-713 using [11C]methyl triflate. Appl Radiat Isot 64:570–573
Toczek MT, Carson RE, Lang L, et al (2003) PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 60:749–756
Toyama H, Ye D, Ichise M, et al (2005) PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur J Nucl Med Mol Imaging 32:593–600
Treiman DM (2001) GABAergic mechanisms in epilepsy. Epilepsia 42(Suppl 3):8–12
Vallabhajosula S, Hirschowitz J, Machac J (1997) Effect of haloperidol dose on 123I-IBZM brain SPECT imaging in schizophrenic patients. J Nucl Med 38:203–207
Verhoeff NP, Wilson AA, Takeshita S, et al (2004) In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry 12:584–595
Volkow ND (2004) Imaging the addicted brain: from molecules to behavior. J Nucl Med 45:(11):13N–24N
Volkow ND, Hitzemann R, Wang GJ, et al (1992) Long-term frontal brain metabolic changes in cocaine dependence and withdrawal. Am J Psychiatry 148:621–626
Volkow ND, Fowler JS, Gatley SJ, et al (1996) PET evaluation of dopamine system of the human brain. J Nucl Med 37:1242–1256
Volkow ND, Fowler JS, Wang G-J (2003) Positron emission tomography and single-photon emission computed tomography in substance abuse research. Semin Nucl Med 34(2):114–128
Waarde A (2000) Measuring receptor occupancy with PET. Curr Pharm Des 6:1593–1610
Wagner HN Jr, Burns HD, Dannals RF, et al (1983) Imaging dopamine receptors in the human brain by positron tomography. Science 221:1264–1266
Wang J, Dickson DW, Trojanowski JQ, et al (1999) The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158:328–337
Wang J, Zuo C-T, Jiang Y-P, et al (2006) 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages. J Neurol 254:185–190
Webster R (2001) Neurotransmitter systems and function: overview. In: Webster RA, (ed) Neurotransmitters, drugs and brain function. Wiley, New York, NY, pp 1–32
Webster R (2001) Other transmitters and mediators. In: Webster RA, ed. Neurotransmitters, drugs and brain function. Wiley, New York, NY, pp 265–286
Whiteman M, Armstrong JS, Chu SH, et al (2004) The novel neuromodulator hydrogen sulfide: an endogenous peroxyni-trite “scavenger”? J Neurochem 90:765–768
Wintermark M, Albers GW, Alexandrov AV (2008) Acute stroke imaging research roadmap. Am J Neuroradiol 29:E23–E30
Zhang MR, Maeda J, Ogawa M, et al (2004) Development of a new radioligand, N-(5-fluoro-2-phenoxyphenyl)-N-(2-[18F] fluoroethyl-5-methoxybenzyl)acetamide, for PET imaging of peripheral benzodiazepine receptor in primate brain. J Med Chem 47:2228–2235
Zhang W, Oya S, Kung MP, et al (2005a) F-18 stilbenes as PET imaging agents for detecting beta-amyloid plaques in the brain. J Med Chem 48: 5980–88
Zhang W, Oya S, Kung MP, et al (2005b) F-18 polyethylenegly-col stilbenes as PET imaging agents targeting A beta aggregates in the brain. Nucl Med Biol 32: 799–809
Zipursky RB, Meyer JH, Verhoeff NP (2007) PET and SPECT imaging in psychiatric disorders. Can J Psychiatry 52: 146–157
Zoghbi SS, Shetty HU, Ichise M, et al (2006) 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med 47:520–527
Zubieta JK, Gorelick DA, Stauffer R, et al (1996) Increased μ-opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 2:1225–1229
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
(2009). Molecular Imaging in Neurology and Psychiatry. In: Molecular Imaging. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-76735-0_16
Download citation
DOI: https://doi.org/10.1007/978-3-540-76735-0_16
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-76734-3
Online ISBN: 978-3-540-76735-0
eBook Packages: MedicineMedicine (R0)